TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25407966

Group type: EXPERIMENTAL
Intervention: Combined treatment group (radiotherapy + LMP1-targeted DNAzyme)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Radiotherapy alone group (radiotherapy + normal saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 22607866

Group type: EXPERIMENTAL
Intervention: XIENCE V (everolimus-eluting stent, EES)
Number of subjects: 324

Group type: COMPARATOR
Intervention: TAXUS Liberté (paclitaxel-eluting stent, PES)
Number of subjects: 324
Study: 20337664

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow graft
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 13
Study: 23135655

Group type: EXPERIMENTAL
Intervention: Cetaphil Dermacontrol Moisturizer (CDM) + tretinoin cream 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: tretinoin cream 0.05%
Number of subjects: 0
Study: 15883262

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg; two 40‐mg tablets once daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 67
Study: 12623831

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% 2D
Number of subjects: 15

Group type: COMPARATOR
Intervention: latanoprost 0.005% 2D
Number of subjects: 15
Study: 9607039

Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 001)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine (lot 003)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral inactivated enterotoxigenic Escherichia coli vaccine
Number of subjects: 0
Study: 7649608

Group type: EXPERIMENTAL
Intervention: Oxyphenonium bromide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 6
Study: 2667153

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice a day for seven days)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Erythromycin (500 mg twice a day for seven days)
Number of subjects: 188
Study: 790287

Group type: EXPERIMENTAL
Intervention: Aerosolized isoproterenol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral theophylline (10 mg/kg three times per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31230766

Group type: EXPERIMENTAL
Intervention: CO2 laser (140Hz, 400μs, 33mJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (35Hz, 297μs, 200mJ, air‐water cooling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scalpel (15c blade)
Number of subjects: 0
Study: 31876726

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Transversus abdominis plane block (TAPB)
Number of subjects: 74
Study: 28551198

Group type: EXPERIMENTAL
Intervention: Parent discouragement of child anger
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Child anger intensity
Number of subjects: 92
Study: 25376189

Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine eye drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25% dextrose orally
Number of subjects: 20
Study: 23483198

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21993434

Group type: EXPERIMENTAL
Intervention: Hoodia gordonii purified extract (HgPE) 1110 mg, 2 servings/day for 15 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hoodia gordonii purified extract (HgPE)
Number of subjects: 49
Study: 18434719

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2422

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2422
Study: 16563397

Group type: EXPERIMENTAL
Intervention: Sickle cell disease (SCD) pregnancies
Number of subjects: 351
Study: 12659615

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 838

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 838
Study: 10632129

Group type: EXPERIMENTAL
Intervention: CHO beverage
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 63

Group type: COMPARATOR
Intervention: CHO beverage and Placebo beverage
Number of subjects: 63
Study: 8813793

Group type: EXPERIMENTAL
Intervention: Iron status measurement (serum concentration of iron, transferrin saturation, TIBC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Stress hypoferraemia response
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hypoferraemia degree
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Iron sequestration recognition
Number of subjects: 36
Study: 1382540

Group type: EXPERIMENTAL
Intervention: Cryotherapy, keratolytic wart paint, and paring
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cryotherapy and inosine pranobex 60 mg/kg/day for 1 week each month
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Paring
Number of subjects: 400
Study: 3886023

Group type: EXPERIMENTAL
Intervention: Vitamin B6 plus magnesium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin B6
Number of subjects: 60

Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 60
Study: 30507409

Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2029
Study: 26752328

Group type: EXPERIMENTAL
Intervention: Individual in vivo exposure therapy (iVET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individual virtual reality exposure therapy (VRET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list
Number of subjects: 60
Study: 24067301

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 22343689

Group type: EXPERIMENTAL
Intervention: 5 ml fibrin sealant
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10 ml fibrin sealant
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study: 20738234

Group type: EXPERIMENTAL
Intervention: Lateral wedge orthoses (5 degrees)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lateral wedge orthoses (8.5 degrees)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No wedge
Number of subjects: 8
Study: 18726956

Group type: COMPARATOR
Intervention: Conventional pressure application for hemostasis (Group I)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Pressure application confirming radial artery patency using Barbeau's test (Group II)
Number of subjects: 436
Study: 15883277

Group type: EXPERIMENTAL
Intervention: Treatment for choroidal melanoma
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 2320
Study: 12374512

Group type: EXPERIMENTAL
Intervention: Active treatment with antihypertensive therapy (nitrendipine 10-40 mg/d, possibly with enalapril maleate 5-20 mg/d and/or hydrochlorothiazide 12.5-25 mg/d)
Number of subjects: 2902

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 2902

Group type: EXPERIMENTAL
Intervention: Active treatment with antihypertensive therapy
Number of subjects: 2902
Study: 10469764

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 1721

Group type: COMPARATOR
Intervention: RSVIG
Number of subjects: 1721

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1721
Study: 7491805

Group type: EXPERIMENTAL
Intervention: new measuring device for intraoperative leg length assessment
Number of subjects: 53
Study: 29843323

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 209

Group type: COMPARATOR
Intervention: Ethacridine dye (Emcredil®)
Number of subjects: 209
Study: 376098

Group type: EXPERIMENTAL
Intervention: Intralesional BCG (IL-BCG)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Multiple puncture vaccination BCG (MPV-BCG)
Number of subjects: 59
Study: 30499618

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus Calcium (1200 mg daily)
Number of subjects: 104
Study: 28333510

Group type: EXPERIMENTAL
Intervention: ADHD treatment (medication + parent training)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Reading treatment (reading instruction)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Combined ADHD + reading treatment
Number of subjects: 216
Study: 26786351

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional low‐fat diet (LFD)
Number of subjects: 70
Study: 25092686

Group type: EXPERIMENTAL
Intervention: β-adrenergic antagonist propranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: T2DM subjects
Number of subjects: 15
Study: 21779819

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40/20 mg
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg (higher-risk subgroup)
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 and 40/20 mg (combined data)
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4216
Study: 19171224

Group type: EXPERIMENTAL
Intervention: Platelet-inhibitory doses of aspirin (maximal total dose: 400mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17685716

Group type: EXPERIMENTAL
Intervention: Incline treadmill training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ground-based resistive training
Number of subjects: 31
Study: 15826746

Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscular monthly)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium and cholecalciferol (500 mg of elemental calcium and 400 IU cholecalciferol daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscular monthly) with calcium and cholecalciferol
Number of subjects: 60
Study: 12547448

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9154784

Group type: EXPERIMENTAL
Intervention: Subcuticular 3-0 polyglactin 910 sutures
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transcutaneous 3-0 nylon sutures
Number of subjects: 54

Group type: COMPARATOR
Intervention: Adhesive strips
Number of subjects: 54
Study: 8199810

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 60 mg/kg infused intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study: 3597737

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (125 transfers)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo (133 transfers)
Number of subjects: 258
Study: 31874497

Group type: EXPERIMENTAL
Intervention: rs7438135 locus in UGT2B7 gene
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rs3732765 locus in P2RY12 gene
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: rs7438135 GA genotype
Number of subjects: 50
Study: 29914050

Group type: EXPERIMENTAL
Intervention: Jawbone UP3
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fitbit Charge Heart Rate
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SenseWear Armband
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Garmin Vivosmart
Number of subjects: 78
Study: 26139360

Group type: EXPERIMENTAL
Intervention: True facilitative KINTAPE
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham KINTAPE
Number of subjects: 64

Group type: COMPARATOR
Intervention: No KINTAPE
Number of subjects: 64
Study: 24277927

Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 22492028

Group type: EXPERIMENTAL
Intervention: Perirhinal-lateral entorhinal pathway
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Parahippocampal-medial entorhinal pathway
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Posterior hippocampus
Number of subjects: 28
Study: 20620788

Group type: EXPERIMENTAL
Intervention: Hamstring donor-site block (20-mL injection of 0.25% bupivacaine)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard treatment (no hamstring donor-site block)
Number of subjects: 27
Study: 18818444

Group type: EXPERIMENTAL
Intervention: Experimental group (n=8) - treadmill walking with rotating visual scene
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=8) - treadmill walking with static visual scene
Number of subjects: 16
Study: 16115337

Group type: EXPERIMENTAL
Intervention: VPP and IPP 1.8 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: VPP and IPP 2.5 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: VPP and IPP 3.6 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 15544888

Group type: EXPERIMENTAL
Intervention: Metronidazole 1600 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 11060718

Group type: EXPERIMENTAL
Intervention: Symptomatic cholinergic strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement, anti-inflammatory agents, free radical scavengers, anti-oxidants, MAO-B inhibitors
Number of subjects: 0
Study: 9196346

Group type: EXPERIMENTAL
Intervention: Fine-bore catheters inserted to 5 cm
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fine-bore catheters inserted to 15 cm
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Catheters inserted into cephalic veins
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Catheters inserted into basilic veins
Number of subjects: 38

Group type: COMPARATOR
Intervention: Overall comparison of catheter lengths
Number of subjects: 38
Study: 8225625

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ceftazidime plus tobramycin
Number of subjects: 89
Study: 3896455

Group type: EXPERIMENTAL
Intervention: Combined therapy with vincristin (1.2 mg/m2), Adriamycin (40 mg/m2), cyclophosphamide (500 mg/m2), and medroxyprogesteron acetate (MPA) (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Alternating therapy with the same combination chemotherapy (VAC) for three cycles alternating with MPA (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Alternating therapy
Number of subjects: 155
Study: 2905566

Group type: EXPERIMENTAL
Intervention: pethidine 1 mg/kg + atropine 0.01 mg/kg
Number of subjects: 186

Group type: COMPARATOR
Intervention: pethidine 1 mg/kg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.5 mg/kg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: alcuronium 0.3 mg/kg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: pancuronium 0.1 mg/kg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg/kg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg/kg
Number of subjects: 186
Study: 31431759

Group type: EXPERIMENTAL
Intervention: Conceptual mapping training (24 six-hour sessions, 3 times a week)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Integration methods training (24 six-hour sessions, 3 times a week)
Number of subjects: 81
Study: 27784211

Group type: EXPERIMENTAL
Intervention: FDSFs (Fast Dissolving Sublingual Films) containing Pullulan with Maltodextrin in a ratio 3:1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FDSFs (Fast Dissolving Sublingual Films)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ventolin® tablets 2 mg
Number of subjects: 14
Study: 25319212

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study: 24196466

Group type: EXPERIMENTAL
Intervention: Topical (intra-articular) tranexamic acid
Number of subjects: 157
Study: 21572327

Group type: EXPERIMENTAL
Intervention: Initial antibiotics administered before shock recognition
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Initial antibiotics administered after shock recognition
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Hourly delays in antibiotic administration after shock recognition
Number of subjects: 291
Study: 19564218

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder Center for Pennsylvanians (BDCP) study intervention
Number of subjects: 515
Study: 17001209

Group type: EXPERIMENTAL
Intervention: Information and health education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (U)
Number of subjects: 0
Study: 15228968

Group type: EXPERIMENTAL
Intervention: Computer-based HIV/AIDS education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counselor-delivered HIV/AIDS education
Number of subjects: 0
Study: 11744790

Group type: EXPERIMENTAL
Intervention: York SF-12
Number of subjects: 2

Group type: COMPARATOR
Intervention: SF-12
Number of subjects: 2
Study: 9279722

Group type: EXPERIMENTAL
Intervention: PM inactivated hepatitis A vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: SB inactivated hepatitis A vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 60
Study: 8393174

Group type: EXPERIMENTAL
Intervention: Soy-protein isolate, lactose-free formula with added soy polysaccharide (group SF, n = 19)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Same diet without added fiber (group S, n = 15)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 3316656

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tutorials
Number of subjects: 0
Study: 29778281

Group type: EXPERIMENTAL
Intervention: Water-drinking test (WDT) in patients on medical treatment for POAG
Number of subjects: 122

Group type: COMPARATOR
Intervention: Water-drinking test (WDT) in control group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination therapy (two or more medications)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 122
Study: 27351217

Group type: EXPERIMENTAL
Intervention: 2L treatment after 1L nab-P+Gem
Number of subjects: 347

Group type: COMPARATOR
Intervention: 2L treatment after 1L Gem
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: 2L therapy containing fluoropyrimidine after 1L nab-P+Gem
Number of subjects: 347

Group type: COMPARATOR
Intervention: 2L therapy containing fluoropyrimidine after 1L Gem
Number of subjects: 347
Study: 25189213

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 23775961

Group type: EXPERIMENTAL
Intervention: Pemetrexed (P) 500 mg/m²
Number of subjects: 205

Group type: COMPARATOR
Intervention: Carboplatin and Pemetrexed (CP) AUC 5 and 500 mg/m²
Number of subjects: 205
Study: 20834082

Group type: COMPARATOR
Intervention: Quinine and placebo (Q+P)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quinine and rabeprazole (Q+R)
Number of subjects: 50
Study: 18256069

Group type: EXPERIMENTAL
Intervention: Infliximab at 3 and 5 mg/kg body weight administered over 24 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 15914575

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12942031

Group type: EXPERIMENTAL
Intervention: Bilevel therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: APAPFOT
Number of subjects: 27
Study: 10481861

Group type: EXPERIMENTAL
Intervention: Induction with vepesid (group 2, trial 1)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Induction without vepesid (group 1, trial 1)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 45 mg/m2 (group 1, trial 2)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 60 mg/m2 (group 3, trial 2)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 45 mg/m2 (group 2, trial 2)
Number of subjects: 408
Study: 8951922

Group type: EXPERIMENTAL
Intervention: High TENS (200 microseconds; 110 Hz)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low TENS (200 microseconds; 4 Hz)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 1952845

Group type: EXPERIMENTAL
Intervention: 400 mg of ketoconazole alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.0 g of sucralfate with 400 mg of ketoconazole
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ranitidine administered 2 h prior to 400 mg of ketoconazole
Number of subjects: 6
Study: 6801962

Group type: EXPERIMENTAL
Intervention: FreAmine II
Number of subjects: 18

Group type: COMPARATOR
Intervention: FreAmine III
Number of subjects: 18
Study: 31736187

Group type: EXPERIMENTAL
Intervention: Stress condition (personalized guided imagery)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neutral condition (personalized guided imagery)
Number of subjects: 70
Study: 30169267

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4) - 15 μg haemagglutinin antigen per strain per 0.5 mL dose; single dose on day 0 for vaccine-primed children, and two doses on days 0 and 28 for vaccine-unprimed children.
Number of subjects: 12018

Group type: COMPARATOR
Intervention: Non-influenza control vaccine (one or two doses).
Number of subjects: 12018

Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 12018
Study: 27221874

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (SQT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 14-day standard triple therapy (STT)
Number of subjects: 100
Study: 24262967

Group type: COMPARATOR
Intervention: Sibutramine therapy
Number of subjects: 101
Study: 22590982

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Breastfeeding irrespective of consumption of other foods
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration longer than 6 months
Number of subjects: 1403